论文部分内容阅读
48例2型糖尿病肾病患者随机分成对照组和治疗组各24例,再根据24小时尿蛋白排泄率(UAER)不同,分为早期肾病组(UAER在20~200μg/min之间)12例和临床期肾病组(UAER大于200μg/min)12例两个亚组。对照组每日静脉滴注PGE1 100μg,疗程14天;治疗组每日静脉点滴阿魏酸钠0.3g、PGE1 100μg,疗程14天。结果:治疗组和对照组治疗后mA、UP、Scr均明显降低,与治疗前比较有显著性差异(P<0.05);治疗后尿蛋白变化与对照组比较也有显著差异(P<0.05)。结论:阿魏酸钠与PGE1联合治疗DN优于单药组。
Forty-eight patients with type 2 diabetic nephropathy were randomly divided into control group and treatment group, 24 cases each. According to the 24-hour urinary protein excretion rate (UAER), 12 cases were divided into early nephropathy group (UAER 20 ~ 200μg / min) Clinical phase nephropathy group (UAER greater than 200μg / min) 12 cases of two subgroups. Control group daily intravenous infusion of PGE1 100μg, treatment for 14 days; the treatment group daily intravenous sodium ferulate 0.3g, PGE1 100μg, treatment for 14 days. Results: After treatment, the levels of mA, UP and Scr in treatment group and control group were significantly lower than those before treatment (P <0.05). The changes of urinary protein in treatment group and control group were also significantly different from those in control group (P <0.05). Conclusion: The combination of sodium ferulate and PGE1 in the treatment of DN is superior to monotherapy group.